Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Gynecologic 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 15Nivolumab 9atezolizumab 5Ipilimumab 4Drug Therapy 4Docetaxel 4Radiotherapy 3Radiosurgery 3Paclitaxel 3Gemcitabine 3Cetuximab 3Carboplatin 3Blood Specimen Collection 3temsirolimus 2spartalizumab 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2entinostat 2durvalumab 2belinostat 2Sirolimus 2Psychiatric Rehabilitation 2Peripheral Blood Stem Cell Transplantation 2Metformin 2Irinotecan 2Fluorouracil 2Etoposide 2Dexamethasone 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Technetium Tc 99m Sestamibi × Thoracic × Clear all
NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡